

Brilliant Violet 785™ anti-human CD34

Catalog # / Size: 2318130 / 100 tests
2318125 / 25 tests

Clone: 561


Isotype: Mouse IgG2a, κ

Reactivity: Human

Preparation: The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 785™ under optimal conditions. The solution is free of unconjugated Brilliant Violet 785™ and unconjugated antibody.

Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).

Concentration: Lot-specific




Human peripheral blood mononuclear cells stained with CD45 PE and CD34 (clone 561) Brilliant Violet 785™ (top) or Brilliant Violet 785™ mouse IgG2a, κ isotype control (bottom). Data shown was gated on CD14⁻ cell population.

Applications:

Applications: Flow Cytometry

Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤5 microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.



Brilliant Violet 785™ excites at 405 nm and emits at 785 nm. The bandpass filter 780/60 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. **Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel.** Refer to your instrument manual or manufacturer for support. Brilliant Violet 785™ is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the

buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

Application Notes: The 561 antibody recognizes a class III group epitope, which is resistant to sialidase/glycolyprotease and chymopapain treatment.

Application References: 1. Croockewit AJ, *et al.* 1998. *Scand. J. Immunol.* 47:82.
2. Rosenzweig M, *et al.* 2001. *J. Med. Primatol.* 30:36.

Description: CD34, also known as gp105-120, is a type I monomeric sialomucin-like glyco-phosphoprotein with an approximate molecular weight of 105-120 kD. It is selectively expressed on the majority of hematopoietic stem/progenitor cells, bone marrow stromal cells, capillary endothelial cells, embryonic fibroblasts, and some nervous tissue. CD34 is a commonly used marker for identifying human hematopoietic stem/progenitor cells. Based on different sensitivities, four groups of epitopes of CD34 have been described. CD34 mediates cell adhesion and lymphocytes homing through binding to L-selectin and E-selectin ligands.